At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 89 enrolled
Drug / intervention
VX-150 +1 moredrug
Likely dose
VX-150 1250 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
In Brief
A Phase 2 clinical trial evaluating VX-150 and Placebo for Small Fiber Neuropathy. Completed, enrolled 89 participants across 34 sites in 4 countries.
Detailed Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy of VX-150 for the treatment of pain caused by small fiber neuropathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Fiber Neuropathy
CountriesGermany, Italy, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedOct 2017
Primary CompletionOct 2018
Study CompletionNov 2018
TodayJul 2026
First PostedOct 9, 2017
Enrollment StartSep 20, 2017
Primary CompletionOct 12, 2018
Study CompletionNov 8, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.7 years ago
Interventions
VX-150drug
Participants received VX-150 1250 milligrams (mg) once daily (qd) orally for 6 weeks.
Placebodrug
Participants received placebo matched to VX-150 for 6 weeks.